Fig. 3.

Immunophenotyping of T cells from syngraft tumors of animals treated with AVA and/or KVax. Tumors and spleens were collected at the efficacy study experimental endpoint from LKR13 bearing mice as shown in Fig. 2. (a) Representative flow cytometry graphs showing CD8+ and IFN-γ staining cells. (b, c) Combined treatment with AVA and KVax promotes increased frequencies of tumor-infiltrating CD8+ T cells. (d, e) Combined treatment with AVA and KVax leads to increased cytokine-producing CD8+ T cells. Data are shown as the mean ± SE of three replicate samples per group, n = 5, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 vs Ctrl, one-way ANOVA.